KR960700056A - Nk1 및 nk2 수용체상에 길항질 효과를 갖는 상승 배합물(synergising association having an antagonist effect on nk1 and nk2 receptors) - Google Patents
Nk1 및 nk2 수용체상에 길항질 효과를 갖는 상승 배합물(synergising association having an antagonist effect on nk1 and nk2 receptors)Info
- Publication number
- KR960700056A KR960700056A KR1019950702980A KR19950702980A KR960700056A KR 960700056 A KR960700056 A KR 960700056A KR 1019950702980 A KR1019950702980 A KR 1019950702980A KR 19950702980 A KR19950702980 A KR 19950702980A KR 960700056 A KR960700056 A KR 960700056A
- Authority
- KR
- South Korea
- Prior art keywords
- group
- derivatives
- receptor
- substituted
- antagonistic activity
- Prior art date
Links
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 title claims abstract 5
- 108010040722 Neurokinin-2 Receptors Proteins 0.000 title claims abstract 3
- 239000005557 antagonist Substances 0.000 title claims 3
- 230000003042 antagnostic effect Effects 0.000 claims abstract 6
- 239000011885 synergistic combination Substances 0.000 claims abstract 4
- 102100037346 Substance-P receptor Human genes 0.000 claims abstract 3
- 102100037342 Substance-K receptor Human genes 0.000 claims abstract 2
- -1 2-substituted-3-aminoquinuclidin group Chemical group 0.000 claims 2
- 150000003053 piperidines Chemical class 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 150000003839 salts Chemical group 0.000 claims 2
- UALFYMMGEYDHHJ-UHFFFAOYSA-N 1-azabicyclo[3.2.2]nonan-3-amine Chemical group C1C(N)CC2CCN1CC2 UALFYMMGEYDHHJ-UHFFFAOYSA-N 0.000 claims 1
- ODSNARDHJFFSRH-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-isoindole Chemical group C1CCCC2CNCC21 ODSNARDHJFFSRH-UHFFFAOYSA-N 0.000 claims 1
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 1
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 abstract 1
- 102400000097 Neurokinin A Human genes 0.000 abstract 1
- 101800000399 Neurokinin A Proteins 0.000 abstract 1
- HEAUFJZALFKPBA-YRVBCFNBSA-N Neurokinin A Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)O)C1=CC=CC=C1 HEAUFJZALFKPBA-YRVBCFNBSA-N 0.000 abstract 1
- 102400000096 Substance P Human genes 0.000 abstract 1
- 101800003906 Substance P Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Soil Working Implements (AREA)
- Plural Heterocyclic Compounds (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Electrotherapy Devices (AREA)
Abstract
NK1 수용체 상에서 길항질 활성을 갖는 하나 이상의 생성물 및 NK2 수용체 상에서 길항질 활성을 갖는 하나 이상의 생성물로 구성되는 것을 특징으로 하는 상승 배합물. 상기 배합물은 물질 P 및/또는 뉴로키닌 A 와 관련된 질병의 치료에 유용하다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (6)
- NK1 수용체에 대한 길항질 활성을 부여받은 하나 이상의 생성물 및 KN2 수용체에 대한 길항질 활성을 부여받은 하나 이상의 생성물로 구성된 것을 특징으로 하는 상승 배합물.
- 제1항에 따른 상승 배합물을 제조하기 위한 NK1 수용체에 대한 길항질 활성을 부여받은 생성물의 사용.
- 제1항에 따른 상승 배합물을 제조하기 위한 KN1 수용체에 대한 길항질 활성을 부여받은 생성물의 사용.
- 임의의 상용가능하고 제약학적으로 허용가능한 부형제 또는 희석제의 존재하에 또는 순수한 상태로 제1항에 따른 배합물로 구성되는 것을 특징으로 하는 제약학적 조성물.
- 제1항에 있어서, 퍼히드로이소인돌 군의 유도체, 2-치환된-3-아미노퀴누클리딘 군의 유도체, 아미노아자비시클로알칸 군의 유도체, 2-치환된-3-아미노피페리딘 군의 유도체, 1-아자비시클로[3.2.2]노난-3-아민 군의 유도체, N-알킬퀴누클리디늄 염 군의 유도체, 슈도펩티드 군의 유도체, 디아실피페라진 군의 유도체, 치환된 방향족 유도체, 디알킬렌피페리디노 유도체, 또는 치환된 피페리딘의 4차 염으로 부터 선택된 NK1수용체의 하나 이상의 길항질로 구성되는 것을 특징으로 하는 배합물.
- 제1항에 있어서, 알릴알킬아민 류의 생성물로부터, α-치환된 폴리펩티드 군으로부터, 또는 피페리딘 유도체 군으로부터 선택된 NK2 수용체의 하나 이상의 길항질로 구성되는 것을 특징으로 하는 배합물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR93-00451 | 1993-01-19 | ||
| FR9300451A FR2700472B1 (fr) | 1993-01-19 | 1993-01-19 | Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2. |
| PCT/FR1994/000055 WO1994016697A1 (fr) | 1993-01-19 | 1994-01-18 | Association synergisante ayant un effet antagoniste des recepteurs nk1 et nk2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR960700056A true KR960700056A (ko) | 1996-01-19 |
| KR100342152B1 KR100342152B1 (ko) | 2003-02-26 |
Family
ID=9443143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019950702980A KR100342152B1 (ko) | 1993-01-19 | 1994-01-18 | Nk1및nk2수용체상에길항질효과를갖는상승배합물 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US6177450B1 (ko) |
| EP (1) | EP0680323B1 (ko) |
| JP (1) | JP4341783B2 (ko) |
| KR (1) | KR100342152B1 (ko) |
| AT (1) | ATE150972T1 (ko) |
| AU (1) | AU682166B2 (ko) |
| BE (1) | BE1006705A3 (ko) |
| CA (1) | CA2152401C (ko) |
| CH (1) | CH687503A5 (ko) |
| DE (1) | DE69402411T2 (ko) |
| DK (1) | DK0680323T3 (ko) |
| ES (2) | ES2100689T3 (ko) |
| FR (1) | FR2700472B1 (ko) |
| GB (1) | GB2274777B (ko) |
| GR (1) | GR3023021T3 (ko) |
| IE (1) | IE940035A1 (ko) |
| IL (1) | IL108356A (ko) |
| IT (1) | IT1269185B (ko) |
| LU (1) | LU88442A1 (ko) |
| NO (1) | NO315077B1 (ko) |
| NZ (1) | NZ259728A (ko) |
| PT (1) | PT101444A (ko) |
| TW (1) | TW381021B (ko) |
| WO (1) | WO1994016697A1 (ko) |
| ZA (1) | ZA94333B (ko) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2287404A (en) * | 1994-03-15 | 1995-09-20 | Pfizer | Antiinflammatory and analgesic compositions |
| WO1996014845A1 (en) * | 1994-11-10 | 1996-05-23 | Pfizer Inc. | Nk-1 receptor antagonists for the treatment of eye disorders |
| US5696267A (en) * | 1995-05-02 | 1997-12-09 | Schering Corporation | Substituted oximes, hydrazones and olefins as neurokinin antagonists |
| US5688960A (en) * | 1995-05-02 | 1997-11-18 | Schering Corporation | Substituted oximes, hydrazones and olefins useful as neurokinin antagonists |
| FR2738245B1 (fr) * | 1995-08-28 | 1997-11-21 | Sanofi Sa | Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant |
| US5691362A (en) * | 1996-06-05 | 1997-11-25 | Schering-Plough Corporation | Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists |
| US5789422A (en) * | 1996-10-28 | 1998-08-04 | Schering Corporation | Substituted arylalkylamines as neurokinin antagonists |
| EP0942732B1 (en) * | 1996-12-02 | 2004-11-17 | MERCK SHARP & DOHME LTD. | Use of nk-1 receptor antagonists for treating movement disorders |
| US6156749A (en) * | 1997-12-01 | 2000-12-05 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating movement disorders |
| GB9816897D0 (en) * | 1998-08-04 | 1998-09-30 | Merck Sharp & Dohme | Therapeutic use |
| FR2792835B3 (fr) * | 1999-04-27 | 2001-05-25 | Sanofi Sa | Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression |
| US20100189797A1 (en) | 2002-06-10 | 2010-07-29 | Julien Mendlewicz | Oral antidepressant formulation |
| EP2158910A1 (en) * | 2003-10-27 | 2010-03-03 | Novartis Ag | Use of neurokinin antagonists in the treatment of urinary incontinence |
| US20080045610A1 (en) * | 2004-09-23 | 2008-02-21 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
| JP2008514612A (ja) * | 2004-09-23 | 2008-05-08 | ミシャロウ、アレクサンダー | 対抗適応を誘発することにより神経伝達物質系を調節する方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5164372A (en) | 1989-04-28 | 1992-11-17 | Fujisawa Pharmaceutical Company, Ltd. | Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same |
| FI97540C (fi) | 1989-11-06 | 1997-01-10 | Sanofi Sa | Menetelmä terapeuttisesti käyttökelpoisten, aromaattisesti substituoitujen piperidiini- ja piperatsiinijohdannaisten valmistamiseksi |
| GB8929070D0 (en) | 1989-12-22 | 1990-02-28 | Fujisawa Pharmaceutical Co | Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same |
| US5232929A (en) | 1990-11-28 | 1993-08-03 | Pfizer Inc. | 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use |
| FR2678267B1 (fr) | 1991-06-25 | 1994-02-04 | Elf Sanofi | Arylalkylamines, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| IL99320A (en) * | 1990-09-05 | 1995-07-31 | Sanofi Sa | Arylalkylamines, their preparation and pharmaceutical preparations containing them |
| GB9023116D0 (en) | 1990-10-24 | 1990-12-05 | Fujisawa Pharmaceutical Co | Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same |
| ATE154354T1 (de) | 1991-02-11 | 1997-06-15 | Merck Sharp & Dohme | Azabicyclische verbindungen, diese enthaltende pharmazeutische zubereitungen und ihre therapeutische verwendung |
| JPH06507402A (ja) | 1991-03-20 | 1994-08-25 | ワーナー−ランバート・コンパニー | 治療活性を有するα−置換ポリペプチド |
| FR2677361A1 (fr) * | 1991-06-04 | 1992-12-11 | Adir | Nouveaux peptides et pseudopeptides, derives de tachykinines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| FR2676054B1 (fr) | 1991-05-03 | 1993-09-03 | Sanofi Elf | Nouveaux composes n-alkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| FR2676055B1 (fr) | 1991-05-03 | 1993-09-03 | Sanofi Elf | Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| FR2676053B1 (fr) | 1991-05-03 | 1993-08-27 | Sanofi Elf | Nouveaux composes dialkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| RU2114848C1 (ru) | 1991-06-20 | 1998-07-10 | Пфайзер Инк. | Фторалкоксибензиламинные производные азотсодержащих гетероциклов, фармацевтическая композиция, способ ингибирования действия вещества р у млекопитающих |
| TW202432B (ko) | 1991-06-21 | 1993-03-21 | Pfizer | |
| US5288730A (en) | 1991-06-24 | 1994-02-22 | Merck Sharp & Dohme Limited | Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy |
| EP0593557B1 (en) | 1991-07-05 | 1996-01-31 | MERCK SHARP & DOHME LTD. | Aromatic compounds, pharmaceutical compositions containing them and their use in therapy |
| EP0536817A1 (en) | 1991-07-05 | 1993-04-14 | MERCK SHARP & DOHME LTD. | Azabicyclic compounds as tachykinin antagonists |
| CA2110514A1 (en) | 1991-07-05 | 1993-01-21 | Raymond Baker | Aromatic compounds, pharmaceutical compositions containing them and their use in therapy |
| US5610183A (en) | 1991-07-10 | 1997-03-11 | Merck, Sharp & Dohme Ltd. | Phenylglycine derivatives pharmaceutical compositions containing them and their use in therapy |
| US5495047A (en) | 1991-07-10 | 1996-02-27 | Merck, Sharp & Dohme (Ltd.) | Fused tricyclic compounds, pharmaceutical compositions containing them and their use in therapy |
| MY110227A (en) | 1991-08-12 | 1998-03-31 | Ciba Geigy Ag | 1-acylpiperindine compounds. |
| US5459270A (en) | 1991-08-20 | 1995-10-17 | Merck Sharp & Dohme Limited | Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them |
| DK0533280T4 (da) | 1991-09-20 | 2005-02-28 | Glaxo Group Ltd | Ny medicinsk anvendelse af tachykininantagonister |
| DK0607164T3 (da) | 1991-09-26 | 2002-06-17 | Pfizer | Kondenserede tricykliske nitrogenholdige heterocykliske forbindelser som substans P-receptorantagonister |
| JP2553020B2 (ja) | 1991-11-07 | 1996-11-13 | 吉富製薬株式会社 | キヌクリジン化合物およびその医薬用途 |
| AU2681392A (en) | 1991-11-12 | 1993-06-15 | Pfizer Inc. | Acyclic ethylenediamine derivatives as substance p receptor antagonists |
| EP0545478A1 (en) | 1991-12-03 | 1993-06-09 | MERCK SHARP & DOHME LTD. | Heterocyclic compounds as tachykinin antagonists |
| GB9201179D0 (en) | 1992-01-21 | 1992-03-11 | Glaxo Group Ltd | Chemical compounds |
| FR2688219B1 (fr) | 1992-03-03 | 1994-07-08 | Sanofi Elf | Sels d'ammonium quaternaires de composes aromatiques amines, leur preparation et compositions pharmaceutiques les contenant. |
| US5328927A (en) | 1992-03-03 | 1994-07-12 | Merck Sharpe & Dohme, Ltd. | Hetercyclic compounds, processes for their preparation and pharmaceutical compositions containing them |
| JP2656702B2 (ja) | 1992-03-23 | 1997-09-24 | ファイザー製薬株式会社 | ペプチド性キヌクリジン |
| FR2689888B1 (fr) | 1992-04-10 | 1994-06-10 | Rhone Poulenc Rorer Sa | Nouveaux derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent. |
| AU675786B2 (en) | 1992-04-15 | 1997-02-20 | Merck Sharp & Dohme Limited | Azacyclic compounds |
| CA2134964C (en) | 1992-05-18 | 1997-12-30 | Manoj C. Desai | Bridged aza-bicyclic derivatives as substance p antagonists |
-
1993
- 1993-01-19 FR FR9300451A patent/FR2700472B1/fr not_active Expired - Fee Related
- 1993-12-22 LU LU88442A patent/LU88442A1/fr unknown
-
1994
- 1994-01-14 GB GB9400691A patent/GB2274777B/en not_active Revoked
- 1994-01-14 IT ITMI940039A patent/IT1269185B/it active IP Right Grant
- 1994-01-17 IL IL10835694A patent/IL108356A/en not_active IP Right Cessation
- 1994-01-18 NZ NZ259728A patent/NZ259728A/en not_active IP Right Cessation
- 1994-01-18 ES ES94904685T patent/ES2100689T3/es not_active Expired - Lifetime
- 1994-01-18 AU AU58627/94A patent/AU682166B2/en not_active Ceased
- 1994-01-18 CH CH00144/94A patent/CH687503A5/fr not_active IP Right Cessation
- 1994-01-18 TW TW083100392A patent/TW381021B/zh not_active IP Right Cessation
- 1994-01-18 CA CA002152401A patent/CA2152401C/fr not_active Expired - Fee Related
- 1994-01-18 AT AT94904685T patent/ATE150972T1/de active
- 1994-01-18 ZA ZA94333A patent/ZA94333B/xx unknown
- 1994-01-18 KR KR1019950702980A patent/KR100342152B1/ko not_active IP Right Cessation
- 1994-01-18 PT PT101444A patent/PT101444A/pt not_active Application Discontinuation
- 1994-01-18 ES ES09400092A patent/ES2091712B1/es not_active Expired - Fee Related
- 1994-01-18 EP EP94904685A patent/EP0680323B1/fr not_active Expired - Lifetime
- 1994-01-18 DE DE69402411T patent/DE69402411T2/de not_active Expired - Lifetime
- 1994-01-18 DK DK94904685.8T patent/DK0680323T3/da active
- 1994-01-18 JP JP51672894A patent/JP4341783B2/ja not_active Expired - Fee Related
- 1994-01-18 IE IE003594A patent/IE940035A1/en not_active IP Right Cessation
- 1994-01-18 WO PCT/FR1994/000055 patent/WO1994016697A1/fr active IP Right Grant
- 1994-01-18 US US08/448,403 patent/US6177450B1/en not_active Expired - Fee Related
- 1994-01-19 BE BE9400063A patent/BE1006705A3/fr not_active IP Right Cessation
-
1995
- 1995-07-17 NO NO19952828A patent/NO315077B1/no not_active IP Right Cessation
-
1997
- 1997-04-03 GR GR960403642T patent/GR3023021T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR960700056A (ko) | Nk1 및 nk2 수용체상에 길항질 효과를 갖는 상승 배합물(synergising association having an antagonist effect on nk1 and nk2 receptors) | |
| DE69405862D1 (de) | Substituierte pyrrolidin-3-alkyl-piperidine verwendbar als tachykinin-antagonisten | |
| CL2003002756A1 (es) | Compuestos derivados de (1-carbamoil-1,1-defenilmetil)-1-[substituido)alquil]purrolidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del sindrome de intestino irritable o incontinencia. | |
| WO1998005292A3 (en) | Piperidine and piperazine derivatives and their use as muscarinic antagonists | |
| DE69715865T2 (de) | Muscarin-antagonisten | |
| ATE147385T1 (de) | Chinuclidin derivat als substanz p antagonist | |
| KR950016738A (ko) | 알쯔하이머 질병의 억제 방법 | |
| CA2191815A1 (en) | Heterocyclic compounds having tachykinin receptor antagonist activity, their preparation and their use | |
| NO960630L (no) | Heterocykler anvendelige som neurokinin antagonister | |
| Witkin et al. | Lethal effects of cocaine are reduced by the dopamine-1 receptor antagonist SCH 23390 but not by haloperidol | |
| KR950016731A (ko) | 지루 및 좌창의 억제 방법 | |
| NO963731L (no) | Behandling av obsessive-kompulsive sykdommer med 5HT2-antagonister | |
| ES2087038A1 (es) | Nuevas piperidinas con actividad antagonista del paf. | |
| PT706395E (pt) | Uso de ropivacaina na preparacao duma composicao farmaceutica com efeito analgesico e bloqueio motor minimo | |
| KR970061248A (ko) | 알츠하이머병 치료용 1, 1, 2-트리페닐부트-1-엔 유도체 | |
| KR930001908A (ko) | 당뇨병에 있어서의 1,4-디히드로피리딘의 용도 | |
| KR960033451A (ko) | 나트륨 치환 트립토판을 포함하는 b형 간염 치료제 | |
| CA2075107A1 (en) | Pharmaceutical composition of dihydropyridine with neuroleptic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20110518 Year of fee payment: 10 |
|
| LAPS | Lapse due to unpaid annual fee |